To access this material please log in or register

Register Authorize

Role of galectin-3 in evaluation of clinical severity of st-elevation myocardial infarction

Fedorova N. V., Kashtalap V. V., Khryachkova O. N., Barbarash O. L.
Federal State Budgetary Institution, “Research Institute for Complex Issues of Cardiovascular Diseases” at the Siberian Branch of the Russian Academy of Medical Sciences, Sosnovy Bulvar 6, Kemerovo 650002

Keywords: galectin-3, ST-segment elevation myocardial infarction, prognosis

DOI: 10.18087/rhj.2015.3.2050

Background. Galectin-3 is a new, extensively studied biomarker, which reflects important pathophysiological processes, such as myocardial inflammation, fibrosis, and remodeling. Aim. To evaluate changes in serum level of galectin-3 in patients with ST-elevation MI (STEMI) during the hospital period and a possibility of using this biomarker for specification of the disease clinical severity. Materials and me­thods. 259 patients diagnosed with STEMI were evaluated. Galectin-3 level was measured using the immunoenzyme assay for all patients at days 10–14 of disease; for 87 of these patients, the measurement was performed also on the first day of disease. Results. On the first day of disease, the galectin-3 concentration was 9.5 (3.3; 11.9) ng / ml, which was significantly higher than the reference value. At 10–14 days, the galectin-3 concentration increased by 60 % and reached 15.6 (9.9; 37.4) ng / ml (р=0.003). For patients of either sex aged 60 and older, the galectin-3 concentration was higher on the first day of disease (10.4 (9.5; 14.5) ng / ml) than for patients younger than 60 (9.5 (8.2; 11.9) ng / ml, р=0.02)). In patients who had previously had MI, the level of galectin-3 at days 10–14 was 14.4 % (р=0.04) higher than in patients without a history of MI. Similar results were obtained for patients with and without a history of acute cerebrovascular disease. At days 10–14 of STEMI, patients with AH differed from patients without AH in higher values of the analyzed biomarker, 10.9 (9.5; 26.2) and 9.5 (9.1; 26.2) ng / ml, respectively (р<0.01). Presence of type 2 DM in patients with STEMI was associated with higher values of galectin-3 both on the first and 10-14th days of MI (р<0.01). The galectin-3 concentration measured at days 10–14 of disease was higher in patients with than without a history of TCI (11.4 (10.9; 11.9) ng / ml and 9.9 (9.1; 10.9) ng / ml. respectively, р=0.02). In patients with LV EF <40 %, the galectin-3 concentration at days 10–14 was significantly higher (р=0.01) than in patients with preserved EF (45.2 (32.8; 49.2) and 10.4 (9.5; 16.8) ng / ml, respectively). At days 10–14, the galectin-3 level was higher in patients with three affected coronary vessels than in patients with only one or two affected coronary arteries (р<0.01) Conclusion. Results of this study showed a possibility of using levels of galectin-3 for evaluation of MI clinical severity. At the same time, this issue requires more detailed and deep insight.
  1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet. 1997 May 17;349 (9063:1436–42.
  2. Chen JS, Ko WJ, Yu HY et al. Analysis of the outcomes for patients experiencing myocardial infarction and cardiopulmonary resuscitation refractory to conventional therapies necessitating extracorporeal life support rescue. Crit Case Med. 2006 Apr;34 (4):950–7.
  3. ВНОК при участии МЗ и Социального развития. Национальные рекомендации по диагностике и лечению больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Кардиоваскулярная терапия и профилактика. 2007;6 (8 прил 1):1–66.
  4. Васильева О. А., Якушева В. Д., Рязанцева Н. В., Новицкий В. В. Возможности использования галектина-3 в лабораторной диагностике. Клинико-лабораторный консилиум. 2011;2:12–5.
  5. Grandin EW, Jarolim P, Murphy SA et al. Galectin-3 and the deve­lopment of HF after Acute Coronary Syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chemistry. 2012 Jan;58 (1):267–73.
  6. De Boer RA, Voors AA, Muntendam P et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009 Sep;11 (9):811–7.
  7. Shah RV, Chen-Tournoux AA, Picard MH et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010 Aug;12 (8):826–32.
  8. Felker GM, Fiuzat M, Shaw LK et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail. 2012 Jan;5 (1):72–8.
  9. Henderson NC, Mackinnon AC, Farnworth SL et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008 Feb;172 (2):288–98.
  10. Sasaki S, Bao Q, Hughes RC. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol. 1999 Mar;187 (4):481–9.
  11. De Boer RA, van Veldhuisen DJ, Gansevoort RT et al. The fibrosis marker galectin-3 and outcome in general population. J Intern Med. 2012 Jul;272 (1):55–64.
  12. Ho JE, Liu C, Lyass A et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012 Oct 2;60 (14):1249–56.
  13. Tsai TH, Sung PH, Chang LT et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012;19 (12):1073–82.
  14. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004 Nov 9;110 (19):3121–8.
  15. Sharma U, Rhaleb NE, Pokharel S et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol. 2008 Mar;294 (3):H1226–32.
  16. Дуболазова Ю. В. Оценка клинического течения хронической сердечной недостаточности с сохраненной фракцией выброса. Автореф. дис. … канд. мед. наук. – М., 2012. – 24с.
  17. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J. 2004;19 (7-9):527–35.
Fedorova N. V., Kashtalap V. V., Khryachkova O. N. et al. Role of galectin-3 in evaluation of clinical severity of st-elevation myocardial infarction. Russian Heart Journal. 2015;14 (3):139–144

To access this material please log in or register

Register Authorize
Ru En